NCT04551430View on ClinicalTrials.gov

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2029

Conditions
Metastatic Soft-tissue Sarcoma
Interventions
DRUG

Cabozantinib

Cabozantinib will be supplied by Exelixis.

DRUG

Nivolumab

Nivolumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.

DRUG

Ipilimumab

Ipilimumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.

Trial Locations (4)

19106

Abramson Cancer Center at Pennsylvania Hospital, Philadelphia

63110

Washington University School of Medicine, St Louis

80045

University of Colorado, Aurora

94305

Stanford University Medical Center, Stanford

Sponsors
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Washington University School of Medicine

OTHER